Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update

被引：51

作者：

Ciarallo, Anthony ^{[1
]}

Rivera, Juan ^{[2
]}

机构：

[1] McGill Univ, Hlth Ctr, Dept Med Imaging, Div Nucl Med, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[2] McGill Univ, Hlth Ctr, Dept Med, Div Endocrinol & Metab, Montreal, PQ, Canada

来源：

AMERICAN JOURNAL OF ROENTGENOLOGY | 2020年 / 215卷 / 02期

关键词：

differentiated thyroid cancer; DTC; I-131; radioactive iodine therapy; RAI; thyroid cancer; RADIOIODINE-REMNANT ABLATION; I-131; METAANALYSIS; PATIENT;

D O I：

10.2214/AJR.19.22626

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

OBJECTIVE. The paradigm of theranostics is based on tailoring therapy for the purpose of optimizing outcomes. This principle is being applied to radioactive iodine therapy. Consequently, thyroid cancer therapy protocols are evolving. The purpose of this article is to promote a modern approach to radioiodine therapy. CONCLUSION. This article highlights guidelines and position statements, summarizes the prognostication systems of thyroid cancer, and reviews which prescribed activities of I-131 are appropriate for each risk category.

引用

页码：285 / 291

页数：7

共 50 条

[21] The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer
Konishi, Kenta
Ishiba, Ryo
Ikenohira, Tsutomu
Asao, Tomoyuki
Hirata, Masanori
Ohira, Keiichi
Komatsu, Tetsuya
Sawada, Michifumi
Tanahashi, Yukichi
Goshima, Satoshi
Magata, Yasuhiro
Nakamura, Katsumasa
ANNALS OF NUCLEAR MEDICINE, 2021, 35 (02) : 159 - 166
[22] Risk Factors for Indeterminate Response After Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
Jeong, Eugene
Yoon, Joon-Kee
Lee, Su Jin
Soh, Euy Young
Lee, Jeonghun
An, Young-Sil
CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 714 - 718
[23] Effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer
An, Jee Hyun
Song, Kee-Ho
Kim, Dong-Lim
Kim, Suk Kyeong
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2017, 45 (01) : 38 - 50
[24] Differentiated thyroid cancer: an update
Wang, Tracy S.
Roman, Sanziana A.
Sosa, Julie A.
CURRENT OPINION IN ONCOLOGY, 2011, 23 (01) : 7 - 12
[25] Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients
Monzen, Satoru
Mariya, Yasushi
Wojcik, Andrzej
Kawamura, Chika
Nakamura, Ayumi
Chiba, Mitsuru
Hosoda, Masahiro
Takai, Yoshihiro
MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (03) : 692 - 698
[26] Birth rates after radioactive iodine treatment for differentiated thyroid cancer
Anderson, Chelsea
Engel, Stephanie M.
Weaver, Mark A.
Zevallos, Jose P.
Nichols, Hazel B.
INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (11) : 2291 - 2295
[27] Radioactive Iodine in Differentiated Carcinoma of Thyroid: An Overview
Singh, Namit Kant
Ramamourthy, Balaji
Hage, Neemu
Nagaraju, Sushmitha
Kappagantu, Krishna Medha
CURRENT RADIOPHARMACEUTICALS, 2024, 17 (01) : 2 - 6
[28] Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer
Worden, Francis
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (06) : 267 - 279
[29] Urinary iodine concentration and radioactive iodine therapeutic response in patients with differentiated thyroid cancer
Jiang, Yuyan
Jin, Jiahui
Fan, Jingzheng
Huang, Chao
Jia, Qiang
Tan, Jian
He, Xianghui
Zheng, Xiangqian
Zhao, Yue
Zhang, Qing
Meng, Zhaowei
Wang, Yan
BIOMARKERS IN MEDICINE, 2021, 15 (11) : 879 - 890
[30] Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Volpe, Fabio
Nappi, Carmela
Zampella, Emilia
Di Donna, Erica
Maurea, Simone
Cuocolo, Alberto
Klain, Michele
CURRENT ONCOLOGY, 2024, 31 (07) : 3870 - 3884

← 1 2 3 4 5 →